who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Don Frieden of P97, Haleh Ardebili of the University of Houston, and Babur Ozden of Aquanta Vision. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from fintech to energy — recently making headlines in Houston innovation.


Don Frieden, president and CEO of P97

Don Frieden, president and CEO of P97, shares how he plans to streamline day-to-day transactions on the Houston Innovators Podcast. Photo courtesy of P97

Before Don Frieden started his company, gas stations hadn't innovated their payment technology since 1997. He knew that needed to change.

P97, founded in 2012, exists to use innovative technologies to simplify and energize daily journeys, Frieden explains on the Houston Innovators Podcast.

"We think about daily journeys from the time we leave home in the morning and when we get back at the end of the day — whether it's tolling, parking, buying fuel, fast food restaurants, it's all a part of your daily journeys, and our goal is to make things a little bit simpler each day," Frieden says on the show. Read more.

Haleh Ardebili, professor of Mechanical Engineering at University of Houston

Haleh Ardebili is the the Bill D. Cook Professor of Mechanical Engineering at UH. Photo courtesy

A new prototype out of the University of Houston feels more like science fiction than reality.

"As a big science fiction fan, I could envision a ‘science-fiction-esque future’ where our clothes are smart, interactive and powered,” according to a statement Haleh Ardebili, who last month published a paper on a new stretchable fabric-based lithium-ion battery in the Extreme Mechanics Letters.

“It seemed a natural next step to create and integrate stretchable batteries with stretchable devices and clothing," she said. "Imagine folding or bending or stretching your laptop or phone in your pocket. Or using interactive sensors embedded in our clothes that monitor our health.”

The battery uses conductive silver fabric as a platform and current collector, which stretches (or mechanically deforms) while allowing movement for electrons and ions. Traditional lithium batteries are quite rigid and use a liquid electrolyte, which are flammable and have potential risks of exploding. Read more.

Babur Ozden, founder of Aquanta Vision

Babur Ozden is the founder of Aquanta Vision. Photo via LinkedIn

Aquanta Vision Technologies, a Houston-based climate-tech startup, was selected to participate in the scale-up phase of Chevron Studio, a Houston program that matches entrepreneurs with technologies to turn them into businesses. Aquanta's computer vision software completely automates the identification of methane in optical gas imaging, or OGI. The technology originated from Colorado State University and CSU STRATA Technology Transfer.

Babur Ozden, a tech startup entrepreneur, along with Marcus Martinez, the lead inventor and Dan Zimmerle, co-inventor and director of METEC at CSU Energy Institute, came up with the technology to identify the presence and motion of methane in live video streams. Currently, this process of identifying methane requires a human camera operator to interpret the images. This can often be unreliable in the collection of emissions data.

Aquanta’s technology requires no human intervention and is universally compatible with all OGI cameras. Currently, only about 10 percent of the 20.5 million surveys done worldwide use this type of technology as it is extremely expensive to produce. Ozden said he hopes Aquanta will change that model.

“What we are doing — we are democratizing this feature, this capability, independent of the camera make and model,” Ozden says. Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted